ImmunityBio IBRX
$6.02 −$0.55 (-8.37%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $6.08 +1.08%
Open$6.41
Prev close$6.57
Day range$6.00 – $6.53
Volume10.64M
Market cap$6.40B
P/E (TTM)–
Dividend yield–
IBRX Stock News
Headlines matching ImmunityBio or the IBRX ticker, most recent first.
- Piper Sandler Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $12
- H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $15
- BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $12
- Earnings Flash (IBRX) ImmunityBio Posts Q2 Net Loss $0.22 a Share, Vs. FactSet Est of $0.08 Loss Negative
- BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Cuts Target Price to $12 Negative
- ImmunityBio (IBRX) Receives a Buy From H.C. Wainwright
- H.C. Wainwright Sticks to Its Buy Rating for ImmunityBio (IBRX)
- Piper Sandler Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $12 Positive
- BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $13
- BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $13 Positive
- BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $9
- H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $15 Positive
- H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $10
- Earnings Flash (IBRX) ImmunityBio Posts Q3 Net Loss $0.18 a Share, Vs. FactSet Est of $0.07 Loss Negative
- Divergence in Insider Trading Among U.S. Biotech Stocks: ImmunityBio (IBRX.US) Sees Largest Cash-Out, While Sellas (SLS.US) Directors Buy In Before 5-Fold Surge Positive
No comments yet — be the first to weigh in on IBRX.
Sign in to join the discussion.